.Pharmacolibrary.Drugs.ATC.B.B03XA07

Information

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used for the treatment of anemia associated with chronic kidney disease (CKD). It stimulates endogenous erythropoietin production, enhances iron metabolism, and is approved in several countries including Japan and the United States.

Pharmacokinetics

Pharmacokinetic parameters for daprodustat in healthy adult volunteers after a single oral administration.

References

1. Mahar, KM, et al., & Goulooze, SC (2024). Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical pharmacokinetics 63(9) 1327–1341. DOI:10.1007/s40262-024-01417-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39259485

2. Bi, YA, et al., & Varma, MVS (2024). Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay. Clinical pharmacology and therapeutics 115(6) 1336–1345. DOI:10.1002/cpt.3215 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38404228

3. Yamada, M, et al., & Mahar, KM (2020). A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat. Clinical pharmacology in drug development 9(8) 978–984. DOI:10.1002/cpdd.793 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32250021

Revisions

• 06/2025 initial generated model